CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
LY2886721 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01534273
NCT01534273Phase 1Completed
CompareCT.gov

Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Feb 16, 2012·Updated Aug 28, 2019

In Brief

A Phase 1 clinical trial evaluating LY2886721 and Placebo for Healthy Volunteers. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 16, 2012
Enrollment StartFeb 1, 2012
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.4 years ago

Interventions

LY2886721drug

Administered orally.

Placebodrug

Administered orally.